Serum interleukin-6 concentration in patients with pemphigus
https://doi.org/10.4081/dr.2024.9868
HTML: 0
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Pemphigus is a rare blistering autoimmune disease that damages the integumentary system and lowers the quality of life of patients. Interleukin-6 (IL-6) has been linked to the immunopathogenesis of pemphigus, according to recent research. Thus, the investigation purpose was to assess the function of IL-6 in the development and intensity of pemphigus disease. Between January 2022 and August 2022, a case-series study involving 26 patients with pemphigus vulgaris (PV), four patients with pemphigus foliaceus (PF), and 20 healthy volunteers was carried out at the Ho Chi Minh City Hospital of Dermato-Venereology. Patients with PV and PF had significantly higher serum IL-6 concentrations than healthy volunteers (p<0.001). Patients with a positive Nikolsky sign had significantly higher serum IL-6 concentrations than those with a negative sign (p<0.001). The serum IL-6 concentration and the pemphigus disease area index were found to significantly correlate (r=0.8, p<0.001). According to our findings, IL-6 might be a significant factor in pemphigus development and severity. Thus, novel treatments that specifically target IL-6 could be a good option for managing pemphigus, particularly in its more severe forms.
Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity 2012;45:7-35.
Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet (London, England). 2019;394:882-94.
Nishifuji K, Amagai M, Kuwana M, et al. Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J Invest Dermatol 2000;114:88-94.
Amagai M, Tanikawa A, Shimizu T, et al. Japanese guidelines for the management of pemphigus. J Dermatol 2014;41:471-86.
Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study. BMJ (Clin Res ed) 2008;337:a180.
Huang YH, Kuo CF, Chen YH, Yang YW. Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population-based study. Invest Dermatol 2012;132:92-7.
Hsu DY, Brieva J, Sinha AA, et al. Comorbidities and inpatient mortality for pemphigus in the U.S.A. Br J Dermatol 2016;174:1290-8.
Masjedi M, Esmaeil N, Saffaei A, et al. Cytokine indexes in pemphigus vulgaris: perception of its immunpathogenesis and hopes for non-steroidal treatment. Iran J Pharma Res 2017;16:1223-9.
D’Auria L, Bonifati C, Mussi A, et al. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw 1997;8:383-7.
López-Robles E, Avalos-Díaz E, Vega-Memije E, et al. TNFalpha and IL-6 are mediators in the blistering process of pemphigus. Int J Dermatol 2001;40:185-8.
Narbutt J, Lukamowicz J, Bogaczewicz J, et al. Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris. Mediators inflamm 2008;2008:875394.
Keskin DB, Stern JN, Fridkis-Hareli M, Razzaque Ahmed A. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy. Cytokine 2008;41:315-21.
Chriguer RS, Roselino AM, de Castro M. Glucocorticoid sensitivity and proinflammatory cytokines pattern in pemphigus. J Clin Immunol 2012;32:786-93.
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014;6:a016295.
Mihara M, Hashizume M, Yoshida H, et al. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (London, England: 1979) 2012;122:143-59.
Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol 2017;13:399-409.
Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol 2016;37:11553-72.
Fu Y, Tang L, Hu M, et al. Changes of serum interleukin-6 in healthy pregnant women and establishment of relevant reference intervals. Clin Chim Acta 2020;502:116-9.
Kishimoto T. Factors affecting B-cell growth and differentiation. Annu Rev Immunol 1985;3:133-57.
Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002;13:357-68.
Metwally D, Fawzy M, ElKalioby M, et al. Assessment of the quality of life, prevalence of depression, and the level of interleukin-6 in patients with pemphigus vulgaris. Acta Dermatovenerol Croat 2020;28:57-62.
Mortazavi H, Esmaili N, Khezri S, et al. The effect of conventional immunosuppressive therapy on cytokine serum levels in pemphigus vulgaris patients. Iran J Allergy Asthma Immunol 2014;13:174-83.
Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004;4:386-91.
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
